Ignite Creation Date:
2024-07-17 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06483334
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-06-21
Brief Title:
A Study of Efficacy and Safety of Sacituzumab Tirumotecan MK-2870 Plus Enfortumab Vedotin EV With and Without Pembrolizumab in Advanced Urothelial Carcinoma MK-3475-04CKEYMAKER-U04
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC